<div class="container">

<table style="width: 100%;"><tr>
<td>E2696</td>
<td style="text-align: right;">R Documentation</td>
</tr></table>
<h2>ECOG E2696 Trial</h2>

<h3>Description</h3>

<p>A data set from the ECOG E2696 trial comparing the combination of the GM2-KLH/QS-21 (GMK) vaccine
and high-dose interferon alfa-2b (IFN) therapy with the GMK vaccine alone in resected high-risk
melanoma patients. The study results were described in Kirkwood et al. (2001) <a href="doi:10.1200/JCO.2001.19.5.1430">doi:10.1200/JCO.2001.19.5.1430</a>.
This data set only includes patients without nodal metastasis.
</p>


<h3>Usage</h3>

<pre><code class="language-R">E2696
</code></pre>


<h3>Format</h3>

<p>A data frame with 105 rows and 6 variables:
</p>

<dl>
<dt>failtime</dt>
<dd>
<p>relapse-free survival (RFS) times (in months)</p>
</dd>
<dt>failind</dt>
<dd>
<p>relapse indicator, 0 = right censored, 1 = relapse</p>
</dd>
<dt>treatment</dt>
<dd>
<p>treatment indicator, 0 = GMK, 1 = GMK and IFN</p>
</dd>
<dt>sex</dt>
<dd>
<p>gender indicator, 0 = male, 1 = female</p>
</dd>
<dt>age</dt>
<dd>
<p>patient age in years</p>
</dd>
<dt>perform</dt>
<dd>
<p>ECOG performance status indicator, 0 = fully active patient, able to
carry on all pre-disease performance without restriction,
1 = restricted in physically strenuous activity, but are ambulatory
and able to carry out work of a light or sedentary nature</p>
</dd>
</dl>
<h3>References</h3>

<p>Kirkwood, J. M., Ibrahim, J., Lawson, D. H., Atkins, M. B., Agarwala, S. S., Collins, K., Mascari, R., Morrissey, D. M., and Chapman, P. B. (2001). High-dose interferon alfa-2b does not diminish antibody response to GM2 vaccination in patients with resected melanoma: Results of the multicenter eastern cooperative oncology group phase II trial E2696. Journal of Clinical Oncology, 19(5), 1430â€“1436.
</p>


</div>